美国 · 平台与数据 · MarketBeat

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

来源：MarketBeat · 美国 1 小时前

vTv Therapeutics (NASDAQ:VTVT) used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician…

在 MarketBeat 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

推荐阅读

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Fifth Third Bancorp (FITB) Posted Strong Q3 2026 Earnings After Its Largest Conversion

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

分享

推荐阅读

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Fifth Third Bancorp (FITB) Posted Strong Q3 2026 Earnings After Its Largest Conversion

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China